# Ipamorelin: Provoking a Gland, Not Supplying a Hormone

> Ipamorelin: Research Overview — The Secretagogue Class — Peptide Broker — A class brief on ipamorelin, the selective growth hormone secretagogue: how a GHS-R1a agonist provokes the pituitary rather than supplying a hormone, what the single Phase 2 trial and the animal record actually showed, and where the class evidence stops.

**CLASS 01 / GROWTH HORMONE SECRETAGOGUE**

Five amino acids that bind the ghrelin receptor on the pituitary and trigger a discrete pulse of the body's own growth hormone — with a selectivity profile that is its defining feature and a human trial record that is one failed study long.

## The short version

Ipamorelin belongs to the class called **growth hormone secretagogues**. The distinction that matters is simple: it does not add growth hormone from outside. It binds a receptor on the pituitary gland and makes the gland release a burst of the hormone it was already able to make.

That receptor, GHS-R1a, is the same one the appetite hormone ghrelin uses. The molecule itself is tiny — five amino acids, several of them in the mirror-image *D* form so that enzymes in the blood cannot chew through them quickly.

Its selling point in the original animal work was selectivity. Older peptides in the same family also pushed up stress and lactation hormones; this one largely did not. Its weak point is the human record. There is one published randomised trial, in surgical patients, and it did not meet its main goal [3]. Almost everything else is animal work or laboratory pharmacology.

## What it is

Ipamorelin is a synthetic pentapeptide with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2. The alpha-aminoisobutyric acid at position one, together with the D-2-naphthylalanine and D-phenylalanine residues, confers resistance to the proteases that would otherwise degrade a short peptide in circulation. Structurally it is derived from the earlier compound GHRP-1 by removal of the central Ala-Trp dipeptide.

Its drug class is a growth hormone secretagogue — specifically a selective agonist of the ghrelin / growth hormone secretagogue receptor, GHS-R1a. It carries no approval as a drug for any indication in any jurisdiction and is marketed only as a research chemical. It is also prohibited in sport at all times under the anti-doping category covering peptide hormones, growth factors and mimetics, with established urine-detection methods in accredited laboratories.

It travels under several names in the literature and in supply listings — NNC 26-0161, ipamorelin acetate — which is worth knowing, because the same molecule appears under different labels in different sources.

## How it works

Ipamorelin selectively activates GHS-R1a on pituitary somatotrophs, the cells that store and release growth hormone, triggering a pulse of secretion. Its signature pharmacological feature is what it does **not** do: unlike the earlier growth-hormone-releasing peptides GHRP-6 and GHRP-2, it does not meaningfully raise ACTH, cortisol or prolactin, even at doses far above the level producing half its maximal growth hormone effect.

The release mechanism is distinct from, and complementary to, that of growth hormone-releasing hormone. That pharmacological fact — two different levers on the same gland — is the entire rationale behind combining a secretagogue with a GHRH analogue such as CJC-1295. It is worth being precise about what that rationale is and is not: it rests on the separate single-agent pharmacology of the two molecules, not on any trial of the combination for any outcome.

GHS-R1a is not confined to the pituitary. The receptor is also expressed on enteric and vagal neurons involved in gastric motility, on pancreatic islet cells where preclinical work has found an insulin-releasing action, and in hypothalamic appetite circuitry — which is why appetite stimulation is a class-level property rather than an incidental side effect.

## What the research shows

**Human pharmacokinetics and the shape of the pulse.** Population PK/PD modelling in healthy male volunteers, with eight subjects per dose level receiving five fifteen-minute intravenous infusions spanning 4.21 to 140.45 nmol/kg, found dose-proportional kinetics: a terminal half-life of approximately two hours, clearance of 0.078 L/h/kg and a steady-state volume of distribution of 0.22 L/kg. The growth hormone response peaked at about 0.67 hours — roughly forty minutes — after dosing, as a single discrete pulse rather than a sustained elevation [4].

**The one controlled human trial, and it failed.** The only published Phase 2 randomised controlled trial of ipamorelin enrolled 114 adults undergoing bowel resection, who received 0.03 mg/kg intravenously twice daily for up to seven days. It missed its primary endpoint: median time to first tolerated meal was 25.3 hours with ipamorelin against 32.6 hours with placebo, a difference that did not reach significance (p=0.15). Treatment-emergent adverse events occurred in 87.5% of the ipamorelin arm and 94.8% of the placebo arm [3].

**Animal evidence for a skeletal effect without an IGF-1 signal.** Subcutaneous ipamorelin at 18, 90 and 450 micrograms per day, divided three times daily for fifteen days, dose-dependently increased the longitudinal bone growth rate of adult female Sprague-Dawley rats from 42 micrometres per day on vehicle to 44, 50 and 52 micrometres per day respectively — with no change in total IGF-1, IGF binding proteins or bone turnover markers [5].

**The most recent in-vivo work.** In a 2024 ferret study, intraperitoneal ipamorelin at 1 to 3 mg/kg inhibited cisplatin-induced body-weight loss by approximately 24% on the last day of the delayed phase, 48 to 72 hours after chemotherapy, but had no anti-emetic effect in either the acute or the delayed phase — in contrast to intracerebroventricular anamorelin, which reduced acute emesis by 60% [1].

**A class-level cardiovascular signal, from a different molecule.** An integrated preclinical safety-pharmacology study of GSK894281, a different GHS-R1a agonist, found dose-dependent myocardial degeneration and necrosis in rats after twenty-eight days of oral dosing, detectable by histopathology and electron microscopy and accompanied by elevated serum heart-type fatty-acid-binding protein at the highest doses, while serum cardiac troponin was not elevated [2]. Ipamorelin itself was not the tested compound; the finding frames why chronic systemic dosing of anything in this class warrants safety scrutiny.

## Reported effects, cautions and safety

**What research-use communities report is anecdotal, not clinical evidence.** The accounts below come from user reports in research-use communities, not from trials. Dose, purity and source are unknown in every case, and no dose is described here.

On the benefit side, the most frequently reported effect by a wide margin is deeper, more restorative sleep, often accompanied in the first week or two by unusually vivid dreams that reporters describe as settling down afterwards. Faster physical recovery and reduced post-training soreness are also frequently reported, and a gradual shift toward leaner body composition over weeks to months is reported occasionally — an account confounded by concurrent diet and training in essentially every case.

On the adverse side, facial flushing and a head-rush shortly after injection is frequently reported and usually described as transient. Occasionally reported effects include tingling or numbness in the hands and feet, mild water retention and puffiness, increased hunger in the hours after dosing, early fatigue or a lightheaded, spacey feeling, injection-site redness and itching, and a diminishing response after several months of continuous use. None of this is a clinical finding.

**Documented cautions.** Growth hormone stimulates hepatic IGF-1 production, and IGF-1 is a well-characterised mitogen that promotes cell proliferation and survival — which is why active or recent malignancy and proliferative conditions are the first flagged concern for anything that raises the growth hormone axis. Growth hormone is also a counter-regulatory hormone that reduces peripheral insulin sensitivity and can raise fasting glucose, and ipamorelin has shown an additional growth-hormone-independent insulinotropic action on pancreatic islet tissue, making impaired glucose tolerance and insulin resistance a second concern. Excess growth hormone is associated with sodium and water retention and expansion of extracellular fluid, so active cardiovascular disease, heart failure and significant oedema are a third — a concern sharpened by the myocardial findings in the related agonist study [2]. Because GHS-R1a agonists activate hypothalamic appetite centres, appetite dysregulation and adiposity-related conditions are a fourth.

The fifth caution is the largest and is about absence rather than presence: long-term human safety is simply uncharacterised. The controlled human dataset consists of one short perioperative Phase 2 trial [3] and one acute single-dose infusion study [4]. No Phase 3 trial has been conducted, and most material in circulation is research-grade of unverified purity from unregulated suppliers.

One genuinely favourable comparative note belongs here too. The selectivity that defines the molecule — minimal ACTH, cortisol and prolactin elevation relative to older growth-hormone-releasing peptides — is a real pharmacological advantage within its class, and is the reason ipamorelin displaced GHRP-6 and GHRP-2 in research interest.

## Where the secretagogue class sits on the map

Ipamorelin is the **amplifier** of this set. It does not deliver a signal; it turns up one the body already produces, which explains almost everything about it.

Because the output is a pulse of endogenous growth hormone, the effects are episodic rather than steady, and the risk profile is inherited wholesale from growth hormone itself rather than invented by the molecule. That is a genuine design advantage — a pulse released by a gland is closer to normal physiology than a flat infusion of recombinant hormone — and it is also why the cautions read like a list of concerns about growth hormone rather than a list of concerns about a peptide.

Against the other three, its position is stark. Tirzepatide's class was developed inside the pharmaceutical system and has phase 3 outcome data measured in thousands of participants. PT-141's class has an approval and a labelled dose. GHK-Cu's class is a cosmetic ingredient with a long topical safety record. The secretagogue class, alone among the four here, has an active commercial promotion far in advance of a trial record that stalled after one negative Phase 2 result — and regulatory access has been tightening rather than loosening. A reader orienting across classes should treat that asymmetry as the headline fact about ipamorelin, not as a footnote to its mechanism.

---

Peptide Broker brokers information, not product: a class-by-class digest of the published peptide literature, with no pharmacy behind it and no dose recommended to anyone.